Norman Ng: China Launched the Category C Drug List to Fill a Critical gap in Its Healthcare Reimbursement System
Norman Ng, Director of Patient Advocacy and Public Affairs of Healthcare Thinkers, shared a post on LinkedIn:
“China launched the Category C Drug List to fill a critical gap in its healthcare reimbursement system.
While Categories A and B cover essential and cost-effective drugs under basic medical insurance, many high-cost, innovative therapies especially for rare diseases or cutting-edge treatments – were left out, forcing patients to pay entirely out-of-pocket.
Category C introduces a new pathway by integrating commercial health insurance to help fund these advanced medicines.
This move aims to:
– Expand access to clinically valuable but expensive drugs
– Reduce financial burden on patients
– Encourage pharmaceutical innovation by improving market incentives
It’s a strategic shift to support innovation while making breakthrough treatments more affordable and accessible.”
More posts featuring Norman Ng on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023